Oxford BioDynamics to expand strategic focus beyond biomarker discovery to development and commercialization of laboratory tests

Innovation Saving Lives

We are a biotechnology company with a proprietary epigenetic biomarker discovery platform, EpiSwitch®, based on the latest advances in regulatory genome architecture and its link to clinical outcomes and patient stratification.

EpiSwitch® biomarkers based on chromosomal conformation signatures are a critical cog in personalised medicine.

Technology to select the right drug at the right dose at the right time for the right patient.

Our Publications on EpiSwitch®

Chromosome conformation signatures as a clinical tool for diagnosis, prognosis and disease understanding in ALS

Salter, M., et. al.,
ENCALS

June 22, 2018

https://www.oxfordbiodynamics.com/wp-content/uploads/2016/10/2018-ENCALS-Chromosome-conformation-signatures-as-a-clinical-tool-for-diagnosis-prognosis-and-disease-understanding-in-ALS.pdf

White blood cells from Prostate cancer patients carry distinct Chromosome Conformations.

Pchejetski, D., et. al.
J of Urology

May 22, 2018

https://www.jurology.com/article/S0022-5347(18)40436-3/pdf

Chromosome conformation signatures response to methotrexate in early rheumatoid arthritis.

Carini et. al.
J Transl Med

January 30, 2018

http://em.rdcu.be/wf/click?upn=KP7O1RED-2BlD0F9LDqGVeSNikQRdSSVno6y1sy5PiGtY-3D_1Xwc2qYR6TifXA9E6uiEHGOeyluJhvI-2BsoiymOjeLDmDhsgq-2BbJrS1iWyD4DsCokgw5J-2B3bme1wt9rQL1jPNrKEjzTH0bn6qR5ZNXKiFtMLgW49uGX8lHedANlmYJiPtQKetB85nI2-2Fygw2eFOzKryJU11Ig7fnQky06uGSbL0kRMmx3Z1UlRwvSOj4YhjgjUdPyQrXAe2DRsMlWr1e0dEbPhgYPENQKNTaKXZ2wEtkRxWvzZzrnDcvZjd3FAYgSy-2BurJe-2BZNifTHuR9l-2Fc8RlzWrudMdGVINHdvg1Y0uzw-3D

A chromosomal conformation signature for a priori prediction of ALS progression subtypes.

Salter, et. al.,
F1000 Research

January 24, 2018

http://dx.doi.org/10.7490/f1000research.1115185.1

Glycaemic progression study among population in Penang, Malaysia.

Patel, JS, et. al.,
Diabetes Asia 2017 Conference

October 13, 2017

http://www.oxfordbiodynamics.com/wp-content/uploads/2016/10/Glycaemic-Progression-Study-Among-Population-in-Penang-Malaysia.pdf

A Prospective Study of Two Distinct Epigenetic Signatures for ALS Diagnosis and Prognosis.

Westra, W, et. al.,
16th Annual Northeast Amyotrophic Lateral Sclerosis Meeting

October 5, 2017

http://www.oxfordbiodynamics.com/wp-content/uploads/2016/10/NEALS_2017_ALS_Biomarker.pdf

Epigenetic signatures and early detection of neurodegenerative diseases: Development of stratifying biomarker for ALS in Asian cohorts.

Lim, CR, et. al.,
World Congress of Neurology

September 25, 2017

https://www.oxfordbiodynamics.com/wp-content/uploads/2016/10/ALSposter_WCN2017Kyoto_Final.pdf

PerkinElmer releases application note outlining the importance of EpiSwitch® technology in determining epigenetic biomarkers using the LabChip GX Touch Platform.

OBD and PerkinElmer
Application Note; 25 August 2017

September 20, 2017

https://www.oxfordbiodynamics.com/wp-content/uploads/2016/10/013589_01EpiGenetics-Biomarkers-APP.pdf

Super-Enhancers and Broad H3K4me3 Domains Form Complex Gene Regulatory Circuits Involving Chromatin Interactions.

Cao, F, et. al.,
Scientific Reports

May 30, 2017

https://www.nature.com/articles/s41598-017-02257-3

Chromatin Conformation Signatures Associated with Epigenetic Deregulation of the FIP1L1 and PDGFRA Genes.

Grand, FH, et. al.,
American Society of Haematology

December 6, 2016

https://ash.confex.com/ash/2016/webprogram/Paper90884.html